Drug producer Takeda opens facilities in Germany and builds in Ireland

The global pharmaceutical producer has opened its new facilities at Oranienburg, Germany while its subsidiary Takeda Ireland has started building a high-containment production facility in Grange Castle, Ireland

Artist's rendering of new production facility at Takeda Ireland when completed

Takeda Pharmaceutical Co has completed the construction of its 21,400m2 manufacturing facilities in Oranienburg, Germany.

The new facility was built at a total cost of around €100m (Y12bn) and is scheduled to begin operating at the end of 2017.

The state of Brandenburg and the German federal government each contributed half of the approximately €23m in subsidies for the plant expansion.

The inauguration ceremonies were attended by the Federal Chancellor of Germany, Angela Merkel, Japan's Ambassador to Germany, Takeshi Yagi, the Federal State Prime Minister of Brandenburg, Dietmar Woidke and Takeda’s President and CEO, Christophe Weber.

Takeda announced in 2014, that as a part of its initiative toward the optimisation of its global network, the manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The completion of this new manufacturing facility in Germany is an integral part of this effort.

The Oranienburg site has a 130-year history of pharmaceutical production and specialises in producing solid forms (pills and capsules).

High containment site in Ireland

Meanwhile construction has also started on a new production facility at Takeda Ireland's Grange Castle site.

Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a standalone, high-containment production facility dedicated to manufacturing its oncology product Ninlaro for global markets.

The construction of the plant will be managed by PM Group with over €40m investment in total. The plant is scheduled to become operational in the second half of 2018.

The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.

The main production facility (ground floor and first floor utilities) will have an area of approx 2,998m2 with ancillary structures (including electrical building, services yard etc.) of approx 2,674m2. The investment will create approximately 40 new jobs over the next two years.

Companies